- Home
- SOPA vs BCAB Comparison
SOPA vs BCAB Comparison
Compare SOPA & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SOPA | BCAB |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9M | 7.4M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SOPA | BCAB |
|---|---|---|
| Price | $0.42 | $5.04 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $22.50 | N/A |
| AVG Volume (30 Days) | ★ 2.6M | 336.4K |
| Earning Date | 05-19-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.86 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,171,635.00 | $300,000.00 |
| Revenue This Year | $2.43 | N/A |
| Revenue Next Year | $71.20 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 45.00 | N/A |
| 52 Week Low | $0.32 | $0.12 |
| 52 Week High | $6.28 | $6.52 |
Technical Indicators
Market Signals| Indicator | SOPA | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 39.31 | 65.21 |
| Support Level | $0.34 | $0.36 |
| Resistance Level | $0.69 | $6.52 |
| Average True Range (ATR) | 0.08 | 0.64 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 32.36 | 42.79 |
Price Performance
Historical ComparisonAbout SOPA Society Pass Incorporated
Society Pass Inc is building an ecosystem of platforms and technology-enabled companies that synergistically work together to transform how consumers and merchants interact with one another in Southeast Asia and South Asia. Through the acquisition of companies and partnerships with entrepreneurs, the company meets the growing demand for services in sectors such as lifestyle, beauty, travel, and food and beverage. The company currently operates in Six reportable operating segments: Online Grocery and Food deliveries, Digital marketing, Online ticketing and reservation, Telecommunications Reseller, e-commerce, and Corporate. The company generates the majority of its revenue from the Digital marketing segment.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.